PURPOSE: In this study, we aimed to evaluate the efficacy and safety of systemic immunosuppression with @entity618 ( @entity2098 ) to prevent corneal graft rejection after high-risk penetrating keratoplasty. METHODS: One hundred and ninety-six consecutive @entity1 who underwent high-risk penetrating keratoplasty defined as the presence of deep vascularization in more than two quadrants, keratouveitis, emergency keratoplasties, and retransplantations were enrolled in the study. Ninety-eight prospectively followed up @entity1 were treated with @entity2098 [with dose adjustment based on @entity3442 ( @entity3443 ) serum concentration], and 98 @entity1 were in the non- @entity2098 -treated retrospectively assessed control group. RESULTS: During a mean of 24  months of observation, immune reactions occurred in eight cases (8  %) and graft rejection with subsequent graft failure occurred in three cases (3  %) in the @entity2098 group. In the control group, graft rejection occurred in 76 cases (78  %) and failure due to graft rejection occurred in 30 cases (31  %). Kaplan-Meier analysis demonstrated that 93  % of the grafts in the @entity2098 -treated group and 47  % in the control group showed no immune rejection (p   <   0.01, log-rank test) after a year. Cox regression analysis proved that @entity2098 treatment decreased the risk of graft rejection 11 times (RR   =   11, 95.0  % CI 4.8-25, p   <   0.0001). Among 98 @entity2098 -treated @entity1 , 13 had gastric discomfort, three developed @entity1210 , and two had @entity417 that resolved after @entity2098 dose reduction. CONCLUSIONS: @entity2098 treatment after high risk penetrating keratoplasty is safe and reduces the incidence of immune graft rejection and graft failure. Side effects were rare and reversible in all but one case.

Systemic immunosuppression with XXXX to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3442 :: ('MESH:D009173', 'Chemical') :: ['mycophenolic acid'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity3443 :: ('D015097', 'Chemical') :: ['MPA'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']
@entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']
